PSMA-11 is a specialized prostate-specific membrane antigen (PSMA) inhibitor designed as a radioligand for targeted imaging and therapy in metastatic castration-resistant prostate cancer. By binding with… Read more
PSMA-11 is a specialized prostate-specific membrane antigen (PSMA) inhibitor designed as a radioligand for targeted imaging and therapy in metastatic castration-resistant prostate cancer. By binding with high affinity to PSMA-expressing tumor cells, this compound facilitates the precise delivery of cytotoxic radiation to malignant sites. Laboratories utilize high-quality PSMA-11 reference standards and related derivatives to conduct essential impurity profiling and analytical method validation. These analytical compounds are critical for ensuring the batch consistency, structural integrity, and regulatory compliance of radiopharmaceutical preparations. By supporting accurate identification and quantification of degradants and synthesis by-products, these reference materials play a vital role in quality control and the development of reliable diagnostic and therapeutic protocols in oncological research.